Drug Profile


Alternative Names: Double-stranded human DNA - Panagen; Fragmented DNA - Panagen; Placental DNA - Panagen; Sodium deoxyribonucleate - Panagen

Latest Information Update: 26 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Panagen LLC
  • Class DNA; Oligonucleotides
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • No development reported Breast cancer

Most Recent Events

  • 26 Jul 2016 No recent reports on development identified - Phase-II for Breast cancer (Combination therapy) in Russia (PO)
  • 01 May 2012 Panagen completes a phase II trial in Breast cancer (combination therapy) in Russia (NCT02115984)
  • 01 May 2010 Phase-II clinical trials in Breast cancer (combination therapy) in Russia (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top